SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DZOO who wrote (166)5/6/1997 7:49:00 AM
From: Dauntless   of 834
 
I have heard that Retavase has been found to be therapeutically equivalent to TPA. It is also priced the same as TPA. Hospitals already geared up for TPA have invested time & money in developing protocols and in training. They have experience and a "comfort factor" with TPA which they are not just going to abandon - especially for something at the same price. In addition, the marketing efforts of the TPA folks are very intensive.

On the clinical side, I believe that Retavase must also be used with heparin and NOVASTAN would likely offer improved performance just as it does with TPA & streptokinase. I'm not a pharmacologist but this is what I've been told.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News